A veteran business executive with 20 years’ experience who has a proven track record in developing life sciences and diagnostics businesses. He has held commercial leadership positions at companies including Definiens, PathAI & HalioDx. He was a key member of the Definiens commercial leadership team who build the tissue biomarker services business and subsequently sold the company to AstraZeneca Medimmune for $150m upfront payment + milestones in Nov 2014.
Thomas has extensive experience in developing technology platform businesses used to help improve and accelerate biomarker development, anatomical pathology, clinical trials and companion diagnostics assays used to aid patient selection for novel drug targeted therapy programs.
